...
Plan | Actual |
Describe Intervention Chosen intervention: Provide Statin Education to providers during regularly scheduled provider meeting – CDPHP to come onsite. Awaiting presentation. Plan for intervention: CDPHP to come onsite for 1-hour educational session during provider meeting on a TBD date. | Chosen Intervention: Statin Education Presentation Date when implemented: scheduled for 8/29/24 Updates: Received presentation from CDPHP on 2/5/24, sent to CMO for approval. CMO approved, date for 1 hour presentation set for 8/29/24 during provider meeting. CDPHP training occurred on 8/29/24. Shared resource from NACHC: recording from NACHC on “Statin Management in High Risk Groups” by Kate Kirley. (additional note: health center is looking to implement POC cholesterol testing) The NACHC “Statin Therapy for High Risk Groups” video will be presented on March 14th at the provider meeting. Video actually presented during meeting on March 15. |
Reach (#/% patients – or providers, for provider-facing interventions – who participated in intervention) | |
Reach of implementers/providers? Planned: 18 providers | Reach of implementers/providers? Actual: 14 providers CDPHP Training: 14 providers |
Reach of patients? Planned: N/A | Reach of patients? Actual: |
Efficacy (Impact of intervention on important outcomes) | |
How will you measure that your intervention is working? Pre/post-test or provider feedback | Were you able to accurately measure how your intervention was working? After training, provider feedback was received. Providers shared that overall the training was effective and they learned things they were not aware of regarding statin therapy. Due to provider survey fatigue, the pre & post tests were not completed, but verbal feedback was encouraged. |
What outcomes do you expect? Improved test score from pre to post-test. | What outcomes have you seen? Providers verbalized the training was helpful and they learned some new things regarding statin therapy intervention. |
How will you ensure your intervention will be effective for your target population? CMO to review presentation for appropriateness. | Did your intervention reach the target population? Intervention scheduled for August, but target population will be all primary care providers at HHC. Intervention reached the primary care providers within the organization. |
What unintended consequences or outcomes might there be? Provider frustration/pushback at pre/post-tests. | What unintended outcomes did you experience? Some providers expressed they’re not “quick to jump on board” with certain aspects, such as placing all diabetes pts in the high risk group statin meds. |
Adoption (#/% and representativeness of staff and sites who implemented the intervention) How did clinicians respond to interventions to intensify medication more rapidly/address therapeutic inertia? | |
Who will deliver the intervention (actually do the work)? Include staff and sites, if applicable. CDPHP to present at Schenectady site in conjunction with CMO/QM. | Who delivered the intervention? Did they have the skills and time needed to complete the intervention? CDPHP will present on 8/29/24. They are highly skilled in the area of statin therapy and provided a very professional and structured training overview to us that will serve to be very beneficial to our providers. They will have a full hour to educate and take questions. 8/29 training session on statin therapy was conducted by a CDPHP representative. |
How will you know if clinicians/care teams/sites used the intervention? Meeting attendance. | What proportion of the planned staff/sites implemented the intervention? All primary care providers attended the training. Were there any differences between care teams/sites who adopted the intervention best vs. others who did not (e.g., differences in staff types, capacity, etc.)? There were no differences noted. |
Implementation Fidelity (How closely the staff/sites followed the intervention design, delivered it as intended – also called fidelity to the intervention) | |
How will you know what adaptations or modifications were made during the intervention? Provider engagement with presenters/CMO. | How did you track modifications during the intervention? Provider engagement with presenters/CMO |
What might be some of the possible obstacles to consistent implementation? Staff call outs/provider schedules. | What were the barriers to consistent intervention implementation? Not all providers present during March 15 meeting. Since the next educational session is set for 8/29/24, it is likely that we will face call outs and/or summer vacations and staff will be out. Slides will be provided to those not in attendance. During the meeting, there were no barriers noted. |
What costs and resources (including time and burden, not just money) need to be considered? Provider Time: 1 hour block to provider schedules | What costs and resources (including time and burden, not just money) need to be considered? Provider schedules are blocked so that they are not seeing patients during this educational session and are uninterrupted. |
How closely did the staff/sites follow the intervention design and deliver as intended? Check all that apply:
Modifications made and other notes: Due to survey fatigue, pre & post tests were not performed. | |
Maintenance (Extent to which intervention is part of routine practices and protocols) | |
What reinforcements will you put in place to sustain the intervention, if effective?
Explain: If proven effective, we may offer regular trainings by CDPHP or other plans. Potentially will develop a protocol. | What reinforcements did you put into place to sustain the intervention?
Explain: Tool developed for providers to assess risk of patients related to stating therapy. |
How will you spread your intervention and lessons learned? Touchbase with providers at 1 mo month post training to get provider feedback on what’s working/what’s not, etc. | How will you spread your intervention and lessons learned? Touchbase with providers at 1 month post training to get provider feedback on what’s working/what’s not, etc. |
What are likely modifications or adaptations that will need to be made to sustain the intervention over time (e.g., lower cost, different staff, reduced intensity, different settings)? Feels the provider buy-in and engagement is present. Have some difficulties coordinating staffing schedules to have all providers present. | |
Intervention #2 Plan | Intervention #2 Actual |
Describe Intervention Chosen intervention: Patient outreach (2) weekly, utilizing Relevant report. Focus on patients with LDL >= 190 who are not on statin. Plan for intervention: Case Manager to outreach via report weekly | Chosen Intervention: Date when implemented: Updates: Set-up an excel spreadsheet on 2/2/24. Will start the week on 2/5/24 outreaching patients. Began reviewing patient charts on 2/5/2024 and will continue on a weekly basis. Relevant report contains a list of patients with Diabetes and who have an LDL >= 190. |
Reach (#/% patients – or providers, for provider-facing interventions – who participated in intervention) | |
Reach of implementers/providers? Planned: N/A | Reach of implementers/providers? Actual: |
Reach of patients? Planned: 40 patients | Reach of patients? Actual: 7 patients as of 2/20/2024. Out of the 7, 1 patient who had an elevated LDL wants to try lifestyle modifications prior to starting a statin. 41 patients by end of June 2024 reached. |
Efficacy (Impact of intervention on important outcomes) | |
How will you measure that your intervention is working? Via monthly data pull of patients with LDL greater than or equal to 190 who are on prescription. | Were you able to accurately measure how your intervention was working? Track quarterly. Review monthly data with HealthEfficient. |
What outcomes do you expect? We would expect that number of patients who have LDL greater than 190 who are actively on prescription would increase. | What outcomes have you seen? Increase noted in prescriptions provided to patients with LDL >= 190 from July 2023 (11.8%) to February 2024 (20.5%). Since the last learning lab, asking patients how are you taking your medications and how often, rather than asking if they’ve filled their Rxs. Implementing this method allows staff to get more information from the patient regarding if they’re taking their Rxs. |
How will you ensure your intervention will be effective for your target population? This will tie back to reports and monthly data. | Did your intervention reach the target population? Targeted outreach via Relevant reports on the LDL>= 190 and Diabetes cohorts. |
What unintended consequences or outcomes might there be? Patient refusal to take statin, refusal to engage in care, inability to contact patient, inability to afford medication. | What unintended outcomes did you experience? 1 patient wanted to try lifestyle modifications prior to starting statin prescription. 1 patient refusing to take statin medication. 1 patient last LDL in 2022, refused to have blood drawn for updated lab: will continue to outreach patient. |
Adoption (#/% and representativeness of staff and sites who implemented the intervention) How did clinicians respond to interventions to intensify medication more rapidly/address therapeutic inertia? | |
Who will deliver the intervention (actually do the work)? Include staff and sites, if applicable. Case Managers in conjunction with the Manager of Case Management. | Who delivered the intervention? Did they have the skills and time needed to complete the intervention? Case Managers in conjunction with the Manager of Case Management. Diabetic educator also encouraged to check for LDL labs, patient names forwarded to Manager of Case Management for f/u. |
How will you know if clinicians/care teams/sites used the intervention? Supervision of spreadsheet by the Manager of Case Management. | What proportion of the planned staff/sites implemented the intervention? Have a shared spreadsheet for both locations. Were there any differences between care teams/sites who adopted the intervention best vs. others who did not (e.g., differences in staff types, capacity, etc.)? Amsterdam providers are performing lower overall than Schenectady providers according to the statin therapy report in Relevant database. OB provider’s patients are at a lower percentage than other providers. |
Implementation Fidelity (How closely the staff/sites followed the intervention design, delivered it as intended – also called fidelity to the intervention) | |
How will you know what adaptations or modifications were made during the intervention? Documentation via spreadsheet. | How did you track modifications during the intervention? Documentation is being maintained regarding patient outreach on spreadsheets. |
What might be some of the possible obstacles to consistent implementation? Decreased staffing in Case Management Department, competing priorities. | What were the barriers to consistent intervention implementation? Time and resources continue to be a barrier to implementation. Also, delay in CLIA certificate for POC cholesterol testing is a barrier. Difficulties contacting some patients: unable to leave voicemails, changing phone numbers, etc. |
What costs and resources (including time and burden, not just money) need to be considered? Time with being short-staffed 2 Case Manager’s. | What costs and resources (including time and burden, not just money) need to be considered? Time and staffing resources continue to be a barrier. As of 3/19/2024 the case management department is fully staffed. |
How closely did the staff/sites follow the intervention design and deliver as intended? Check all that apply:
Modifications made and other notes: | |
Maintenance (Extent to which intervention is part of routine practices and protocols) | |
What reinforcements will you put in place to sustain the intervention, if effective?
Explain: Pulling monthly data, reporting out to CM staff on updates | What reinforcements did you put into place to sustain the intervention?
Explain: Discussion with CMO regarding policy/procedure on how often cholesterol screenings should be performed/follow-up visits should be scheduled after medication changes. Had 1:1 meeting with CMO and discussed items noted above. Will validate if this language is within the policy. |
How will you spread your intervention and lessons learned? Discuss at Interdepartmental/Quality Meetings, Statin (Diabetics) Quality Dashboard inclusion. | How will you spread your intervention and lessons learned? Qualitymeeting scheduled for May. Will discuss at interdepartmental meetings (April meeting cancelled, will plan for May). Intervention has also been applied to the Diabetes education program. Cholesterol testing & lipid lowering therapy included on PVP reports, which is provided daily to care teams. |
What are likely modifications or adaptations that will need to be made to sustain the intervention over time (e.g., lower cost, different staff, reduced intensity, different settings)? Will likely discuss as a topic at case manager meetings regularly. Case manager meetings occurring weekly. Intervention has also been applied to the Diabetes education program. Staffing capacity and time. | |
...
| Change History |
|---|